Pancreatic Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Pancreatic Cancer, including details on symptoms, causes, treatment, information. | ||||||||
|
Ski promotes tumor growth through abrogation of transforming growth factor-beta signaling in pancreatic cancer.Heider TR, Lyman S, Schoonhoven R, Behrns KE Department of Surgery, Division of Gastrointestinal Surgery, University of North Carolina, Chapel Hill, NC, USA. OBJECTIVE: We hypothesized that human pancreatic cancer resists TGF-beta signaling and cell death through increased Ski expression. SUMMARY BACKGROUND DATA: Ski is an oncogenic protein that acts as a TGF-beta repressor and prevents related gene transcription. Previous work suggests that Ski acts as an oncoprotein in melanoma and esophageal cancer. Ski expression and function have not been determined in human pancreatic cancer. METHODS: Immunohistochemistry and immunoblots assessed Ski expression in human pancreatic cancer. Panc-1 cells were treated with or without Ski siRNA, and Ski and Smad protein expression, transcriptional reporter activation, and growth assays were determined. Panc-1 cells were inoculated in the flank of nude mice and tumor volume and histology assessed after administration of Ski siRNA or control vector. RESULTS: Ski was abundantly expressed in human pancreatic cancer specimens assessed by immunohistochemistry (91%) and immunoblot analysis (67%). Panc-1 cells exhibited nascent Ski expression that was maximally inhibited 48 hours after transfection with Ski siRNA. TGF-beta transcriptional activity was increased 2.5-fold in Ski siRNA-treated cells compared with control (P < 0.05). Ski siRNA increased TGF-beta-induced Smad2 phosphorylation and p21 expression. Panc-1 growth in culture was decreased 2-fold at 72 hours. A Ski siRNA expression vector injected into nude mice resulted in a 5-fold decrease in growth. CONCLUSION: Inhibition of Ski through RNA interference restored TGF-beta signaling and growth inhibition in vitro, and decreased tumor growth in vivo. Published 26 June 2007 in Ann Surg, 246(1): 61-8.
© 2004-2008 Pancreatic Cancer Research Today. All Rights Reserved. |
| ||||||
